ADVERSE REACTIONS SECTION.

6 ADVERSE REACTIONS. The following adverse reactions are discussed in greater detail in other sections of the labeling:Proteinuria [see Warnings and Precautions (5.1)] Hypersensitivity [see Warnings and Precautions (5.2)] Proteinuria [see Warnings and Precautions (5.1)] Hypersensitivity [see Warnings and Precautions (5.2)] Most common adverse reactions (>=10%) are nausea, diarrhea or soft stools, oral ulcers, rash, fatigue, fever, arthralgia, proteinuria, and emesis. (6)To report SUSPECTED ADVERSE REACTIONS, contact Teva at 1-888-838-2872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.. 6.1Clinical Trials Experience. Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of the drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.Adverse reactions occurring at an incidence of >=5% in an uncontrolled trial in 66 patients with cystinuria age to 68 years are shown in the table below. Patients in group had previously been treated with d-penicillamine; those in group had not. Of those patients who had stopped taking d-penicillamine due to toxicity (34 out of 49 patients in group 1), 22 were able to continue treatment with tiopronin. In those without prior history of d-penicillamine treatment, 6% developed reactions of sufficient severity to require tiopronin withdrawal.Table presents adverse reactions >=5% in either treatment group occurring in this trial.Table 1: Adverse Reactions Occurring in One or More PatientsSystem Organ ClassAdverse ReactionGroup Previously treated withd-penicillamine (N=49)Group Naive to d-penicillamine(N=17)Blood and Lymphatic System Disordersanemia1 (2%)1 (6%)Gastrointestinal Disordersnausea12 (25%)2 (12%)emesis5 (10%)-diarrhea/soft stools9 (18%)1 (6%)abdominal pain-1 (6%)oral ulcers6 (12%)3 (18%)General Disorders and Administration Site Conditionsfever4 (8%)-weakness2 (4%)2 (12%)fatigue7 (14%)-peripheral (edema)3 (6%)1 (6%)chest pain-1 (6%)Metabolism and Nutrition Disordersanorexia4 (8%)-Musculoskeletal and Connective Tissue Disordersarthralgia-2 (12%)Renal and Urinary Disordersproteinuria5 (10%)1 (6%)impotence-1 (6%)Respiratory, Thoracic and Mediastinal Disorderscough-1 (6%)Skin and Subcutaneous Tissue Disordersrash7 (14%)2 (12%)ecchymosis3 (6%)-pruritus2 (4%)1 (6%)urticaria4 (8%)-skin wrinkling3 (6%)1 (6%)Taste DisturbanceA reduction in taste perception may develop. It is believed to be the result of chelation of trace metals by tiopronin. Hypogeusia is often self-limited.. 6.2Postmarketing Experience. Adverse reactions have been reported from the literature, as well as during post-approval use of tiopronin. Because the post-approval reactions are reported voluntarily from population of uncertain size, it is not always possible to reliably estimate their frequency or establish causal relationship to tiopronin exposure.Adverse reactions reported during the postmarketing use of tiopronin are listed by body system in Table 2.Table 2: Adverse Reactions Reported for Tiopronin Pharmacovigilance by System Organ Class and Preferred TermSystem Organ ClassPreferred TermCardiac Disorderscongestive heart failureEar and Labyrinth DisordervertigoGastrointestinal Disordersabdominal discomfort; abdominal distension; abdominal pain; chapped lips; diarrhea; dry mouth; dyspepsia; eructation; flatulence; gastrointestinal disorder; gastroesophageal reflux disease; nausea; vomiting; jaundice; liver transaminitisGeneral Disorders and Administration Site Conditionsasthenia; chest pain; fatigue; malaise; pain; peripheral swelling; pyrexia; swellingInvestigationsglomerular filtration rate decreased; weight increasedMetabolism and Nutrition Disordersdecreased appetite; dehydration; hypophagiaMusculoskeletal and Connective Tissue Disordersarthralgia; back pain; flank pain; joint swelling; limb discomfort; musculoskeletal discomfort; myalgia; neck pain; pain in extremityNervous System Disordersageusia; burning sensation; dizziness; dysgeusia; headache; hypoesthesiaRenal and Urinary Disordersnephrotic syndrome; proteinuria; renal failureSkin and Subcutaneous Tissue Disordersdry skin; hyperhidrosis; pemphigus foliaceus; pruritus; rash; rash pruritic; skin irritation; skin texture abnormal; skin wrinkling; urticaria.

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION.

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility. CarcinogenesisLong-term carcinogenicity studies in animals have not been performed.MutagenesisTiopronin was not genotoxic in the chromosomal aberration, sister chromatid exchange, and in vivo micronucleus assays.Impairment of FertilityHigh doses of tiopronin in experimental animals have been shown to interfere with maintenance of pregnancy and viability of the fetus. In published male fertility studies in rats, tiopronin at 20 mg/kg/day intramuscular (IM) for 60 days induced reductions in testis, epididymis, vas deferens, and accessory sex glands weights and in the count and motility of cauda epididymal sperm.

CLINICAL PHARMACOLOGY SECTION.

12 CLINICAL PHARMACOLOGY. 12.1 Mechanism of Action. The goal of therapy is to reduce urinary cystine concentration below its solubility limit. Tiopronin is an active reducing agent which undergoes thiol-disulfide exchange with cystine to form mixed disulfide of tiopronin-cysteine. From this reaction, water-soluble mixed disulfide is formed and the amount of sparingly soluble cystine is reduced.. 12.2 Pharmacodynamics. The decrement in urinary cystine produced by tiopronin is generally proportional to the dose. reduction in urinary cystine of 250 to 350 mg/day at tiopronin dosage of g/day, and decline of approximately 500 mg/day at dosage of g/day, might be expected. Tiopronin has rapid onset and offset of action, showing fall in cystine excretion on the first day of administration and rise on the first day of drug withdrawal.. 12.3 Pharmacokinetics. AbsorptionTiopronin Delayed-Release TabletsWhen tiopronin immediate-release tablet and tiopronin delayed-release tablet single doses were given to fasted healthy subjects the median time to peak plasma levels (Tmax) was (range: 0.5 to 2.1) and (range: 1.0 to 6.0) hours, respectively. The peak exposure (Cmax) and total exposure (AUC0-t) of tiopronin from tiopronin delayed-release tablets were decreased by 22% and 7% respectively compared to tiopronin immediate-release tablets.EliminationExcretionWhen tiopronin is given orally, up to 48% of dose appears in urine during the first hours and up to 78% by 72 hours.Drug InteractionsAlcoholAn in vitro dissolution study was conducted to evaluate the impact of alcohol (5, 10, 20, and 40%) on the dose dumping of tiopronin delayed-release tablets. The study results showed that the addition of alcohol to the dissolution media increases the dissolution rate of tiopronin delayed-release tablets in the acidic media of 0.1N HCl [see Drug Interactions (7.1)].

CONTRAINDICATIONS SECTION.

4 CONTRAINDICATIONS. Tiopronin delayed-release tablets are contraindicated in patients with hypersensitivity to tiopronin or any other components of tiopronin delayed-release tablets [see Warnings and Precautions (5.2)].. Hypersensitivity to tiopronin or any component of tiopronin delayed-release tablets (4). Hypersensitivity to tiopronin or any component of tiopronin delayed-release tablets (4).

DESCRIPTION SECTION.

11 DESCRIPTION. Tiopronin delayed-release tablets are reducing and cystine-binding thiol drug (CBTD) for oral use. Tiopronin is N-(2-Mercaptopropionyl) glycine and has the following structure:Tiopronin has the empirical formula C5H9NO3S and molecular weight of 163.20. In this drug product tiopronin exists as dl racemic mixture.Tiopronin is white to off-white crystalline powder, which is freely soluble in water.Each tiopronin delayed-release tablet contains 100 mg or 300 mg of tiopronin. The inactive ingredients in tiopronin delayed-release tablets include ammonium hydroxide, black iron oxide, colloidal silicon dioxide, hydroxypropyl cellulose, hypromellose 2910, lactose monohydrate, low-substituted hydroxypropyl cellulose, magnesium stearate, methacrylic acid ethyl acrylate copolymer, propylene glycol, shellac glaze, talc, and triethyl citrate.. new.

DOSAGE & ADMINISTRATION SECTION.

2 DOSAGE AND ADMINISTRATION. The recommended initial dosage in adult patients is 800 mg/day. In clinical studies, the average dosage was about 1,000 mg/day. (2.1)The recommended initial dosage in pediatric patients years of age and older is 15 mg/kg/day. Avoid dosages greater than 50 mg/kg per day in pediatric patients. (5.1, 8.4)Measure urinary cystine month after initiation of tiopronin delayed-release tablets and every months thereafter (2.3)Administer tiopronin delayed-release tablets in divided doses at the same times each day, without food. (2.1). The recommended initial dosage in adult patients is 800 mg/day. In clinical studies, the average dosage was about 1,000 mg/day. (2.1). The recommended initial dosage in pediatric patients years of age and older is 15 mg/kg/day. Avoid dosages greater than 50 mg/kg per day in pediatric patients. (5.1, 8.4). Measure urinary cystine month after initiation of tiopronin delayed-release tablets and every months thereafter (2.3). Administer tiopronin delayed-release tablets in divided doses at the same times each day, without food. (2.1). 2.1Recommended Dosage. Adults: The recommended initial dosage in adult patients is 800 mg/day. In clinical studies, the average dosage was about 1,000 mg/day.Pediatrics: The recommended initial dosage in pediatric patients years of age and older is 15 mg/kg/day. Avoid dosages greater than 50 mg/kg per day in pediatric patients [see Warnings and Precautions (5.1), Use in Specific Populations (8.4)].Administer tiopronin delayed-release tablets in divided doses at the same times each day, without food. Consider starting tiopronin delayed-release tablets at lower dosage in patients with history of severe toxicity to d-penicillamine.Additional pediatric use information is approved for Mission Pharmacal Companys Thiola EC (tiopronin delayed-release) tablets. However, due to Mission Pharmacal Companys marketing exclusivity rights, this drug product is not labeled with that information.. 2.3Monitoring. Measure urinary cystine month after starting tiopronin delayed-release tablets and every months thereafter. Adjust tiopronin delayed-release tablets dosage to maintain urinary cystine concentration less than 250 mg/L.Assess for proteinuria before treatment and every to months during treatment [see Warnings and Precautions (5.1)].Discontinue tiopronin delayed-release tablets in patients who develop proteinuria, and monitor urinary protein and renal function. Consider restarting tiopronin delayed-release tablets treatment at lower dosage after resolution of proteinuria.

DOSAGE FORMS & STRENGTHS SECTION.

3 DOSAGE FORMS AND STRENGTHS. Tablets for oral use:100 mg tablets: White to off-white, round, biconvex, film-coated tablets imprinted with R1 on one side in black ink. 300 mg tablets: White to off-white, round, biconvex, film-coated tablets imprinted with R3 on one side in black ink. Tablets: 100 mg and 300 mg (3).

DRUG INTERACTIONS SECTION.

7 DRUG INTERACTIONS. 7.1Alcohol. Tiopronin is released faster from tiopronin delayed-release tablets in the presence of alcohol and the risk for adverse events associated with tiopronin delayed-release tablets when taken with alcohol is unknown. Avoid alcohol consumption hours before and hours after taking tiopronin delayed-release tablets [see Clinical Pharmacology (12.3)].

GERIATRIC USE SECTION.

8.5 Geriatric Use. This drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

HOW SUPPLIED SECTION.

16 HOW SUPPLIED/STORAGE AND HANDLING. Tiopronin delayed-release tablets are available as follows:100 mg: Each white to off-white, round, biconvex, film-coated tablet imprinted with R1 on one side in black ink contains 100 mg of tiopronin. Tablets are supplied in bottles of 300 (NDC 0480-9227-55).300 mg: Each white to off-white, round, biconvex, film-coated tablet imprinted with R3 on one side in black ink contains 300 mg of tiopronin. Tablets are supplied in bottles of 90 (NDC 0480-7824-98).Store at 25C (77F); excursions permitted to 15 to 30C (59 to 86F) [see USP Controlled Room Temperature].

INDICATIONS & USAGE SECTION.

1 INDICATIONS AND USAGE. Tiopronin delayed-release tablets are indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients years of age and older with severe homozygous cystinuria, who are not responsive to these measures alone.Additional pediatric use information is approved for Mission Pharmacal Companys Thiola EC (tiopronin delayed-release) tablets. However, due to Mission Pharmacal Companys marketing exclusivity rights, this drug product is not labeled with that information.. Tiopronin delayed-release tablets are reducing and complexing thiol indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients years of age and older with severe homozygous cystinuria, who are not responsive to these measures alone. (1).

INFORMATION FOR PATIENTS SECTION.

17 PATIENT COUNSELING INFORMATION. LactationAdvise women that breastfeeding is not recommended during treatment with tiopronin delayed-release tablets [see Use in Specific Populations (8.2)].Manufactured In India By: Watson Pharma Private Limited Verna, Salcette Goa 403 722 INDIAManufactured For: Teva Pharmaceuticals Parsippany, NJ 07054Iss. 6/2024.

LACTATION SECTION.

8.2 Lactation. Risk SummaryThere are no data on the presence of tiopronin in either human or animal milk or on the effects of the breastfed child. published study suggests that tiopronin may suppress milk production. Because of the potential for serious adverse reactions, including nephrotic syndrome, advise patients that breastfeeding is not recommended during treatment with tiopronin delayed-release tablets.

MECHANISM OF ACTION SECTION.

12.1 Mechanism of Action. The goal of therapy is to reduce urinary cystine concentration below its solubility limit. Tiopronin is an active reducing agent which undergoes thiol-disulfide exchange with cystine to form mixed disulfide of tiopronin-cysteine. From this reaction, water-soluble mixed disulfide is formed and the amount of sparingly soluble cystine is reduced.

NONCLINICAL TOXICOLOGY SECTION.

13 NONCLINICAL TOXICOLOGY. 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility. CarcinogenesisLong-term carcinogenicity studies in animals have not been performed.MutagenesisTiopronin was not genotoxic in the chromosomal aberration, sister chromatid exchange, and in vivo micronucleus assays.Impairment of FertilityHigh doses of tiopronin in experimental animals have been shown to interfere with maintenance of pregnancy and viability of the fetus. In published male fertility studies in rats, tiopronin at 20 mg/kg/day intramuscular (IM) for 60 days induced reductions in testis, epididymis, vas deferens, and accessory sex glands weights and in the count and motility of cauda epididymal sperm.

OVERDOSAGE SECTION.

10 OVERDOSAGE. There is no information on overdosage with tiopronin.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL. NDC 0480-9227-55Tiopronin Delayed-Release Tablets100 mgRx only300 Tablets. launch.

PEDIATRIC USE SECTION.

8.4 Pediatric Use. Tiopronin delayed-release tablets are indicated in pediatric patients years of age and older with severe homozygous cystinuria, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation who are not responsive to these measures alone. This indication is based on safety and efficacy data from trial in patients years to 68 years of age and clinical experience. Proteinuria, including nephrotic syndrome, has been reported in pediatric patients. Pediatric patients receiving greater than 50 mg/kg tiopronin per day may be at greater risk [see Dosage and Administration (2.1, 2.3), Warnings and Precautions (5.1) and Adverse Reactions (6.1)].Tiopronin delayed-release tablets are not approved for use in pediatric patients weighing less than 20 kg or in pediatric patients unable to swallow tablets [see Dosage and Administration (2.1)].Additional pediatric use information is approved for Mission Pharmacal Companys Thiola EC (tiopronin delayed-release) tablets. However, due to Mission Pharmacal Companys marketing exclusivity rights, this drug product is not labeled with that information.

PHARMACODYNAMICS SECTION.

12.2 Pharmacodynamics. The decrement in urinary cystine produced by tiopronin is generally proportional to the dose. reduction in urinary cystine of 250 to 350 mg/day at tiopronin dosage of g/day, and decline of approximately 500 mg/day at dosage of g/day, might be expected. Tiopronin has rapid onset and offset of action, showing fall in cystine excretion on the first day of administration and rise on the first day of drug withdrawal.

PHARMACOKINETICS SECTION.

12.3 Pharmacokinetics. AbsorptionTiopronin Delayed-Release TabletsWhen tiopronin immediate-release tablet and tiopronin delayed-release tablet single doses were given to fasted healthy subjects the median time to peak plasma levels (Tmax) was (range: 0.5 to 2.1) and (range: 1.0 to 6.0) hours, respectively. The peak exposure (Cmax) and total exposure (AUC0-t) of tiopronin from tiopronin delayed-release tablets were decreased by 22% and 7% respectively compared to tiopronin immediate-release tablets.EliminationExcretionWhen tiopronin is given orally, up to 48% of dose appears in urine during the first hours and up to 78% by 72 hours.Drug InteractionsAlcoholAn in vitro dissolution study was conducted to evaluate the impact of alcohol (5, 10, 20, and 40%) on the dose dumping of tiopronin delayed-release tablets. The study results showed that the addition of alcohol to the dissolution media increases the dissolution rate of tiopronin delayed-release tablets in the acidic media of 0.1N HCl [see Drug Interactions (7.1)].

PREGNANCY SECTION.

8.1 Pregnancy. Risk SummaryAvailable published case report data with tiopronin have not identified drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. Renal stones in pregnancy may result in adverse pregnancy outcomes (see Clinical Considerations). In animal reproduction studies, there were no adverse developmental outcomes with oral administration of tiopronin to pregnant mice and rats during organogenesis at doses up to times 2 grams/day human dose (based on mg/m2). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2% to 4% and 15% to 20%, respectively.Clinical ConsiderationsDisease-associated maternal and/or embryo/fetal riskRenal stones in pregnancy may increase the risk of adverse pregnancy outcomes, such as preterm birth and low birth weight.DataAnimal DataNo findings of fetal malformations could be attributed to the drug in reproduction studies in mice and rats at doses up to times the highest recommended human dose of grams/day (based on mg/m2).

SPL UNCLASSIFIED SECTION.

2.1Recommended Dosage. Adults: The recommended initial dosage in adult patients is 800 mg/day. In clinical studies, the average dosage was about 1,000 mg/day.Pediatrics: The recommended initial dosage in pediatric patients years of age and older is 15 mg/kg/day. Avoid dosages greater than 50 mg/kg per day in pediatric patients [see Warnings and Precautions (5.1), Use in Specific Populations (8.4)].Administer tiopronin delayed-release tablets in divided doses at the same times each day, without food. Consider starting tiopronin delayed-release tablets at lower dosage in patients with history of severe toxicity to d-penicillamine.Additional pediatric use information is approved for Mission Pharmacal Companys Thiola EC (tiopronin delayed-release) tablets. However, due to Mission Pharmacal Companys marketing exclusivity rights, this drug product is not labeled with that information.

USE IN SPECIFIC POPULATIONS SECTION.

8 USE IN SPECIFIC POPULATIONS. Lactation: Breastfeeding is not recommended. (8.2)Geriatric: Choose dose carefully and monitor renal function in the elderly. (8.5) Additional pediatric use information is approved for Mission Pharmacal Companys Thiola EC (tiopronin delayed-release) tablets. However, due to Mission Pharmacal Companys marketing exclusivity rights, this drug product is not labeled with that information. Lactation: Breastfeeding is not recommended. (8.2). Geriatric: Choose dose carefully and monitor renal function in the elderly. (8.5) 8.1 Pregnancy. Risk SummaryAvailable published case report data with tiopronin have not identified drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. Renal stones in pregnancy may result in adverse pregnancy outcomes (see Clinical Considerations). In animal reproduction studies, there were no adverse developmental outcomes with oral administration of tiopronin to pregnant mice and rats during organogenesis at doses up to times 2 grams/day human dose (based on mg/m2). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2% to 4% and 15% to 20%, respectively.Clinical ConsiderationsDisease-associated maternal and/or embryo/fetal riskRenal stones in pregnancy may increase the risk of adverse pregnancy outcomes, such as preterm birth and low birth weight.DataAnimal DataNo findings of fetal malformations could be attributed to the drug in reproduction studies in mice and rats at doses up to times the highest recommended human dose of grams/day (based on mg/m2).. 8.2 Lactation. Risk SummaryThere are no data on the presence of tiopronin in either human or animal milk or on the effects of the breastfed child. published study suggests that tiopronin may suppress milk production. Because of the potential for serious adverse reactions, including nephrotic syndrome, advise patients that breastfeeding is not recommended during treatment with tiopronin delayed-release tablets.. 8.4 Pediatric Use. Tiopronin delayed-release tablets are indicated in pediatric patients years of age and older with severe homozygous cystinuria, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation who are not responsive to these measures alone. This indication is based on safety and efficacy data from trial in patients years to 68 years of age and clinical experience. Proteinuria, including nephrotic syndrome, has been reported in pediatric patients. Pediatric patients receiving greater than 50 mg/kg tiopronin per day may be at greater risk [see Dosage and Administration (2.1, 2.3), Warnings and Precautions (5.1) and Adverse Reactions (6.1)].Tiopronin delayed-release tablets are not approved for use in pediatric patients weighing less than 20 kg or in pediatric patients unable to swallow tablets [see Dosage and Administration (2.1)].Additional pediatric use information is approved for Mission Pharmacal Companys Thiola EC (tiopronin delayed-release) tablets. However, due to Mission Pharmacal Companys marketing exclusivity rights, this drug product is not labeled with that information.. 8.5 Geriatric Use. This drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

WARNINGS AND PRECAUTIONS SECTION.

5 WARNINGS AND PRECAUTIONS. Proteinuria, including nephrotic syndrome, and membranous nephropathy, has been reported with tiopronin use. Pediatric patients receiving greater than 50 mg/kg of tiopronin per day may be at increased risk for proteinuria. (2.1, 5.1, 8.4)Hypersensitivity reactions have been reported during tiopronin treatment. (4, 5.2). Proteinuria, including nephrotic syndrome, and membranous nephropathy, has been reported with tiopronin use. Pediatric patients receiving greater than 50 mg/kg of tiopronin per day may be at increased risk for proteinuria. (2.1, 5.1, 8.4). Hypersensitivity reactions have been reported during tiopronin treatment. (4, 5.2). 5.1Proteinuria. Proteinuria, including nephrotic syndrome, and membranous nephropathy, have been reported with tiopronin use. Pediatric patients receiving greater than 50 mg/kg of tiopronin per day may be at increased risk for proteinuria [see Dosage and Administration (2.3), Adverse Reactions (6.1, 6.2) Use in Specific Populations (8.4)]. Monitor patients for the development of proteinuria and discontinue therapy in patients who develop proteinuria [see Dosage and Administration (2.3)].. 5.2Hypersensitivity Reactions. Hypersensitivity reactions (drug fever, rash, fever, arthralgia and lymphadenopathy) have been reported [see Contraindications (4)].